



July 31, 2025

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400 051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

**Sub: Press Release and presentation on the financials and operational performance of the Company for the first quarter ended June 30, 2025**

Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

In continuation of our letter dated July 23, 2025, regarding the Investors Conference Call scheduled to be held later during the day i.e. Thursday, July 31, 2025, please find enclosed the Press Release and presentation that will be discussed during the meeting. The above details will also be available on the website of the Company at [www.jubilantingrevia.com](http://www.jubilantingrevia.com).

We request you to take the same on record.

Thanking you

Yours faithfully,

For Jubilant Ingrevia Limited

Deepanjali Gulati  
Company Secretary

Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Ingrevia Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantingrevia.com](http://www.jubilantingrevia.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
Uttar Pradesh, India  
CIN : L24299UP2019PLC122657

**Jubilant Ingrevia Limited**

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubilantingrevia.com

**PRESS RELEASE**Noida, Tuesday, July 31<sup>st</sup>, 2025**JUBILANT INGREVIA LIMITED – Q1'FY26 RESULTS**

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Total Revenue	1,024	1,051	1,038	-1%	1%
Total EBITDA	119	155	153	-1%	29%
EBITDA Margin (%)	12%	15%	15%		
Profit After Tax	49	74	75	1%	54%
Profit After Tax Margin (%)	5%	7%	7%		
Basic and Diluted EPS (Rs.)	3.1	4.7	4.7	1%	54%

1. All figures are in Rs Crore unless otherwise stated

The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter ended June 30<sup>th</sup>, 2025.

**Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said:**

*"We are pleased to present the financial results for the first quarter of this fiscal year. Our specialty chemical businesses have continued to perform strongly, growing double digit YoY and with stable performance on QoQ basis. Our Chemical Intermediates business has started to recover marginally with QoQ growth. Ongoing cost optimisation initiatives have further enhanced profitability, with EBITDA for the quarter rising by 29% YoY and Profit After Tax increasing by an impressive 54% YoY.*

**Markets Update:**

*The **global chemicals sector** is emerging from the inventory destocking phase. Specialty chemicals are seeing volume growth, though pricing remains stable. Commodity segments continue to face demand challenges, with prices stabilising at lower levels. **China +1 macro-trend** is creating more opportunities for us, especially in our specialty chemicals segment where we are witnessing healthy funnel across sub-segments.*

*The **Pharmaceutical end-use** market continues to show steady growth, driven by stable pricing and consistent volumes growth across various derivatives as well as Intermediates segments.*

*The **Agrochemical sector** continues its upward momentum, driven by strong volume growth both on YoY and QoQ basis. Average prices have been stable for last few quarters now.*

*The **Nutrition market** saw stable volumes during the quarter. Niacinamide demand remained muted as customers delayed purchases amid competitive offerings, while choline demand rose notably, with prices holding steady.*

**Business Update:**

***Specialty Chemicals** saw stable volumes, with growth led by Pyridine and Diketene derivatives and CDMO sales. Pharma end-use sales posted strong YoY demand growth with steady pricing. Agriculture end-use segment showed modest volume gains, stable pricing, and normalized inventories. CDMO volumes rose sharply on YoY basis, supported by proprietary agro and pharma order sales.*

***The Nutrition and Health Solutions** Business segment witnessed substantial YoY volume growth, primarily fueled by significant increases in Cosmetic-grade demand, with new cGMP facility receiving exceptional response. Feed volumes remained low due to cautious buying by the customers, with marginal price softening. Choline products*



saw sustained YoY growth, and the EU's anti-dumping duty on China is expected to strengthen Jubilant's position in Choline Chloride market. We are already in touch with multiple EU customers for choline chloride sales.

**In Chemical Intermediates segment**, our strategic push towards Ethyl Acetate, led to a YoY increase in volumes. Acetic Anhydride volumes also recovered sequentially, with marginal uptick in demand from Agrochem sector. Overall, pricing in the segment stayed relatively muted. We continued with our cost focus in this quarter to improve the margins vs. last quarter.

#### **Future Outlook:**

For FY26, we anticipate continued growth and improved performance, driven by advancements in our Specialty Chemicals and Nutrition businesses, and expected recovery in Acetyls portfolio. Alongside we remain committed towards our Lean 2.0 cost efficiency initiatives. We are on track to deliver the big CDMO order in early 2026, which should further accelerate our growth trajectory in coming quarters."

**Commenting on the Company's performance, Mr. Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited said:**

*"The financial results for Q1FY26 are in line with our Pinnacle strategy which is reflected in the continued growth momentum, driven by the Specialty & Nutrition segment. In our CDMO business, the pharmaceutical segment saw a significant expansion in its opportunity pipeline, with the funnel doubling in size in last few months. This growth was driven by strong traction from innovative pharmaceutical companies and Tier-1 CDMOs across key global markets including the EU, US, and Japan. With above progress, we are confident that our topline and margins will continue to show the expected growth trajectory in coming quarters"*

**Let me share a few highlights to demonstrate the progress:**

- 1) *The Specialty & Nutrition segment continues to maintain a steady and dominant position, demonstrating significantly improved customer engagement that is actively fueling a strong and expanding business pipeline. This portfolio now contributes approximately 63% of the company's total revenue and an impressive 90% of its EBITDA, underscoring its strategic importance.*
- 2) *Our core product platforms continued to drive growth and leadership in Q1 of FY26.*
  - a) *Within the Pyridine and Picoline segment, we successfully maintained our global leadership and market share in both Pyridine and Beta-Picoline.*
  - b) *Under our Fine Chemicals business, we sustained a robust growth trajectory, delivering over 15% year-on-year growth. Our leadership position across a broad portfolio of 36 Pyridine derivatives remained intact, supported by strong customer engagement and operational excellence. We also witnessed encouraging momentum in our Diketene derivatives segment, characterised by high capacity utilisation levels. To support future growth and meet rising demand, we have already initiated capacity debottlenecking and expansion efforts for new product lines. Additionally, we expanded our cosmetic ingredients portfolio during the quarter, which has seen promising initial traction, particularly with key multinational customers.*
  - c) *Under our CDMO business, the Pharma segment saw a significant expansion in its opportunity pipeline, with the funnel doubling in size in last few months. This growth was driven by strong traction with innovative pharmaceutical companies and Tier-1 CDMOs across key global markets including the EU, US, and Japan. In the Agro segment, we started deliveries for first agro contract, progressed well on plant construction for the second one, and continued several other discussions with innovators. In the Semiconductor segment, we now have over 12 opportunities in the pipeline, reflecting growing interest*

and demand. To support this momentum, we have made strategic investments in R&D and established a dedicated team focused on advancing our capabilities and offerings in this space.

- d) *Under our Nutrition business, we continued to maintain our leadership position in Vitamin B3, particularly in the animal feed segment. Additionally, we are actively ramping up our presence in the cosmetic and food-grade segments, supported by the commissioning of our new production facility. In Animal Nutrition, we are witnessing strong traction in export markets, especially across Europe, with our specialty portfolio registering double-digit growth across markets. On the Human Nutrition front, we have established a dedicated team that is now scaling up efforts in Choline Chloride and Choline Bitartrate, and also developing several pre-mix solutions for marquee customers. Furthermore, 2–3 new molecules are currently in the pipeline, aimed at expanding our offerings and strengthening our position in human nutrition segment.*
  - e) *In the Acetyls segment, we successfully retained our market share in both domestic and EU markets for Acetic Anhydride, reaffirming our position as a reliable supplier in these geographies. Additionally, we achieved volume growth across other key products, including Ethyl Acetate and Acetaldehyde, driven by consistent demand and operational efficiency. Throughout the quarter, we maintained a strong focus on cost optimization initiatives and have actively pursued capacity debottlenecking measures to support future scalability and enhance throughput across our product lines.*
  - 3) *The Key Account Management initiative is gaining momentum, evidenced by a noticeable increase in inbound inquiries across Pharma, Agrochemicals, Semiconductors, Cosmetics and Nutrition segments. Currently, there are over 70 high-priority opportunities being actively pursued within the sales funnel, reflecting robust market interest and potential for future growth.*
  - 4) *To further capitalize on KAM momentum, we have strengthened our Business Development teams across key geographies including the U.S., European Union, and Japan, enabling deeper customer engagement and broader market coverage.*
  - 5) *As a result, we are witnessing a notable increase in revenue contribution from the U.S and Rest of the World (ROW) markets, with the U.S. revenue growing by 11% year-over-year and ROW revenue surging by an impressive 45% year-over-year. This growth has been primarily driven by the strong performance of our Specialty Chemicals and Nutrition business segments.*
  - 6) *We are actively upgrading our plants through a sustained focus on Safety, ESG and the disciplined implementation of 5S methodologies. As part of our Lean 2.0 cost optimisation program, we have set a target of achieving annualised savings exceeding Rs 100+ crore in FY26, and have progressed well in Q1. In parallel, we have initiated the integration of Generative AI within our R&D functions, aimed at accelerating pipeline development and enhancing agility in product innovation and formulation processes.*
  - 7) *On the capex front*
    - a) *We continue to make strategic investments to support future growth, with key capital expenditure milestones being successfully achieved.*
    - b) *We successfully completed the plant modification for our first key agro CDMO order, and started the deliveries with a 'First Time Right' approach in Q1FY26.*
    - c) *Also, Capex execution remains on track for the \$300 million big Agro contract, and we expect to start the supplies early 2026.*
-



- d) The commissioning of the new boiler at our Bharuch facility is scheduled for Q2 of FY26, with more than 99% work already completed.
- e) In addition, debottlenecking initiatives are actively underway to unlock additional capacity across our core platforms, including diketene and pyridine.
- f) We have also commenced detailed engineering work for a new Multi-Purpose Plant (MPP) at our Gajraula site, further reinforcing our commitment to expanding capabilities and supporting long-term demand. We expect to start the construction in next few months.

With above progress, we are confident that our topline and margins will continue to show the expected growth trajectory in next few quarters”.

## Q1'FY26 Highlights | Segment Wise Analysis

### A. Specialty Chemicals

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	431	487	478	-2%	11%
% Share of Overall Revenue	42%	46%	46%		
EBITDA	86	129	130	1%	52%
% EBITDA Margin	20%	27%	27%		
% Contribution to EBITDA <sup>2</sup>	59%	76%	76%		

1. All figures are in Rs Crore unless otherwise stated

2. Before adjustment of Unallocated corporate expense/income

### Market Highlights

#### Pharma

- Continued improvement in demand observed
- YoY demand growth remained strong
- Steady pricing trend maintained

#### Agrochemical

- Volumes showed modest, gradual growth
- Stable pricing trend observed
- Inventory levels stabilizing post-destocking

#### CDMO

- Increased traction from customers across Pharma, Agro and semi-conductor segments, driven by supply chain diversification imperatives
- Traction with cosmetics and nutrition customers as well

### Business Drivers

- Segment revenue growth was led by higher Fine Chemicals and CDMO sales
- Margins continued to remain elevated on account of :
  - Higher sales from high margin orders within Specialty portfolio
  - Steady pricing in select Pyridine and Diketene Derivatives
  - Continuous cost optimisations measures undertaken

## B. Nutrition & Health Solutions

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	186	190	179	-6%	-4%
% Share of Overall Revenue	18%	18%	17%		
EBITDA	23	29	25	-16%	8%
% EBITDA Margin	12%	16%	14%		
% Contribution to EBITDA <sup>2</sup>	16%	17%	14%		

1. All figures are in Rs Crore unless otherwise stated

2. Before adjustment of Unallocated corporate expense/Income

### Market Highlights

#### Feed B3

- Volumes were low as buyers delayed shipments, opting to maintain lower inventory levels
- Overall Pricing witnessed modest softening

#### Food & Cosmetic B3

- Cosmetic-grade demand surged on both QoQ and YoY basis
- New cGMP facility receiving exceptional response
- Steady sequential growth in food grade volumes

#### Choline

- Sustained strong YoY volume traction
- EU's anti-dumping duty on China, to boost Jubilant's competitive edge in Choline Chloride

### Business Drivers

- Revenue saw a modest decline, impacted by lower Niacinamide prices and shipment delays as customers opted for lean inventories
- YoY increase in Choline Chloride volumes and animal nutrition specialty business
- The sequential drop in EBITDA was mainly driven by lower volumes and prices of Niacinamide

## C. Chemical Intermediates Segment

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	408	375	381	2%	-7%
% Share of Overall Revenue	40%	36%	37%		
EBITDA	36	10	17	63%	-53%
% EBITDA Margin	9%	3%	4%		
% Contribution to EBITDA <sup>2</sup>	25%	6%	10%		

1. All figures are in Rs Crore unless otherwise stated

2. Before adjustment of Unallocated corporate expense/Income

### Market Highlights

#### Volumes

- Acetic Anhydride volumes saw an uptick during the quarter driven by recovery in agrochem segments
- Ethyl Acetate volumes remained a key area of strategic emphasis

### Cost

- Acetic Acid prices declined marginally during the quarter
- Through ongoing cost optimization measures and easing freight rates, margin expansion expected in few quarters

### Price

- Segment prices remained steady on a sequential basis

### Business Drivers

- Revenue improved QoQ, supported by an increase in Acetic Anhydride volumes
- EBITDA improved sequentially, supported by higher Acetic Anhydride volumes and a slight reduction in input costs for Acetic Acid

## 3. Income Statement – Q1'FY26

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	QoQ	YoY
<b>Revenue from operations</b>					
a) Sales/Income from operations	1010	1038	1029	-1%	2%
b) Other operating income	14	13	9	-35%	-39%
<b>Total revenue from operations</b>	<b>1024</b>	<b>1051</b>	<b>1038</b>	<b>-1%</b>	<b>1%</b>
Other income	10	8	11	34%	17%
<b>Total income</b>	<b>1034</b>	<b>1060</b>	<b>1049</b>	<b>-1%</b>	<b>1%</b>
<b>Expenses</b>					
a) Cost of materials consumed	532	481	449	-7%	-16%
b) Purchases of stock-in-trade	7	32	32	1%	338%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	-11	20	38	94%	-453%
d) Employee benefits expense	102	96	108	13%	6%
e) Finance costs	14	14	13	-9%	-11%
f) Depreciation and amortisation expense	39	39	41	4%	5%
g) Other expenses:					
- Power and fuel expense	118	104	100	-4%	-15%
- Others	166	171	168	-2%	1%
<b>Total expenses</b>	<b>968</b>	<b>958</b>	<b>949</b>	<b>-1%</b>	<b>-2%</b>
Profit before share of loss of an associate (3-4)	66	102	100	-2%	51%
Share of loss of an associate	0		0		
<b>Profit before tax</b>	<b>66</b>	<b>102</b>	<b>100</b>	<b>-2%</b>	<b>51%</b>
<b>Tax expense</b>					
- Current tax	12	25	23	-8%	86%
- Deferred tax charge	5	2	2		
<b>Net profit for the period/year</b>	<b>49</b>	<b>74</b>	<b>75</b>	<b>1%</b>	<b>54%</b>
Earnings per share of ₹ 1 each					
Basic (₹)	3.1	4.7	4.7		
Diluted (₹)	3.1	4.6	4.7		

All figures are in Rs Crore unless otherwise stated

#### 4. Segment P&L – Q1'FY26

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	QoQ (%)	YoY (%)
<b>Revenue</b>					
Speciality Chemicals	431	487	478	(2%)	11%
Nutrition & Health Solutions	186	190	179	(6%)	(4%)
Chemical Intermediates	408	375	381	2%	(7%)
<b>Total Revenue from Operations</b>	<b>1,024</b>	<b>1,051</b>	<b>1,038</b>	<b>(1%)</b>	<b>1%</b>
<b>Reported EBITDA</b>	<b>119</b>	<b>155</b>	<b>153</b>	<b>(1%)</b>	<b>29%</b>
Speciality Chemicals	86	129	130	1%	52%
Nutrition & Health Solutions	23	29	25	(16%)	8%
Chemical Intermediates	36	10	17	63%	(53%)
Unallocated Corporate & One-Off (Expenses)/Income	-25	-14	-19	-	-
<b>PAT</b>	<b>49</b>	<b>74</b>	<b>75</b>	<b>1%</b>	<b>54%</b>
<b>EPS</b>	<b>3.1</b>	<b>4.7</b>	<b>4.7</b>	<b>1%</b>	<b>54%</b>
<b>Reported EBITDA Margins</b>	<b>12%</b>	<b>15%</b>	<b>15%</b>		
Speciality Chemicals	20%	27%	27%		
Nutrition & Health Solutions	12%	16%	14%		
Chemical Intermediates	9%	3%	4%		
<b>Net Margin</b>	<b>5%</b>	<b>7%</b>	<b>7%</b>		

All figures are in Rs Crore unless otherwise stated

#### 5. Debt Position as on 30<sup>th</sup> June, 2025

Particulars <sup>1</sup>	30-Jun-24	31-Mar-25	30-Jun-25
Long Term Borrowings	450	453	448
Short Term Borrowings	291	303	360
<b>Total Gross Debt</b>	<b>741</b>	<b>756</b>	<b>808</b>
Cash & Equivalent	64	98	107
<b>Total Net Debt</b>	<b>677</b>	<b>658</b>	<b>700</b>
YoY change			3%

All figures are in Rs Crore unless otherwise stated

- The capex for the quarter was Rs 54 Crore, which was primarily utilized towards the upcoming CDMO Plant at Bharuch



## About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a globally integrated Life Sciences & Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad portfolio of over 130+ products and customised solutions that are innovative, cost-effective and conform to global quality standards.

It has over 40 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharmaceuticals, agrochemicals and semiconductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50 plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ 150 scientists working on cutting-edge research and innovation.

Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies.

For more information, please visit: [www.jubilantingrevia.com](http://www.jubilantingrevia.com).

## For more information, please contact:

### For Investors

Pavleen Taneja  
Jubilant Ingrevia Limited  
Ph: +91-120 436 1000  
E-mail: [pavleen.taneja@jubl.com](mailto:pavleen.taneja@jubl.com)

Siddharth Rangnekar  
CDR India  
Ph: +91 22 6645 1209  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

### For Media

Sandipan Ghatak  
Ph: +919810776182  
E-mail: [sandipan.ghatak@jubl.com](mailto:sandipan.ghatak@jubl.com)

Sahir Seth  
M: +91 9999270119  
E-mail: [sahir.seth@adfactorspr.com](mailto:sahir.seth@adfactorspr.com)

---

**Earnings Call details:** The company will host earnings call at 5.00 PM IST on 31<sup>st</sup> July, 2025

Diamond Pass Log-In	
Pre-registration:	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p>  <a href="#">Click here to Express/Join the Call</a> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode &amp; pin to connect to call.</p>
Conference Dial-In Numbers	
Universal Access:	<p><b>+ 91 22 6280 1141</b> <b>+ 91 22 7115 8042</b></p>
Toll Free Number:	<p>USA: <b>1 866 746 2133</b> UK: <b>0 808 101 1573</b> Singapore: <b>800 101 2045</b> Hong Kong: <b>800 964 448</b></p>
Audio Link:	<p>The Audio link will be available on the company website. Please access the link here - <a href="https://jubilantingrevia.com/investors/financials/quarterly-results">https://jubilantingrevia.com/investors/financials/quarterly-results</a></p>

#### Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.






# Investor Presentation


---

July 2025

**Innovating for a Sustainable Future**



# Disclaimer




Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

## NOTES:

1. The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary
2. Closing Exchange Rate for USD 1 at Rs 85.76 as on June 30, 2025 and Rs 85.5 as on March 31, 2025.

# Chairmen's Message on Q1'FY26 Financial Results | 1/2



*"We are pleased to present the financial results for the first quarter of this fiscal year. Our specialty chemical businesses have continued to perform strongly, growing double digit YoY and with stable performance on QoQ basis. Our Chemical Intermediates business has started to recover marginally with QoQ growth. Ongoing cost optimization initiatives have further enhanced profitability, with EBITDA for the quarter rising by 29% YoY and Profit After Tax increasing by an impressive 54% YoY.*

## Markets Update:

*The **global chemicals sector** is emerging from the inventory destocking phase. Specialty chemicals are seeing volume growth, though pricing remains stable. Commodity segments continue to face demand challenges, with prices stabilizing at lower levels. **China +1 macro-trend** is creating more opportunities for us, especially in our specialty chemicals segment where we are witnessing healthy funnel across sub-segments.*

*The **Pharmaceutical end-use** market continues to show steady growth, driven by stable pricing and consistent volumes growth across various derivatives as well as Intermediates segments.*

*The **Agrochemical sector** continues its upward momentum, driven by strong volume growth both on YoY and QoQ basis. Average prices have been stable for last few quarters now.*

*The **Nutrition market** saw stable volumes during the quarter. Niacinamide demand remained muted as customers delayed purchases amid competitive offerings, while choline demand rose notably, with prices holding steady.*

**Mr. Shyam S Bhartia**

Chairman  
&

**Mr. Hari S Bhartia**

Co-Chairman

# Chairmen's Message on Q1'FY26 Financial Results | 2/2



**Mr. Shyam S Bhartia**  
Chairman  
&  
**Mr. Hari S Bhartia**  
Co-Chairman

## **Business Update:**

**Specialty Chemicals** saw stable volumes, with growth led by Pyridine and Diketene derivatives and CDMO sales. Pharma end-use sales posted strong YoY demand growth with steady pricing. Agriculture end-use segment showed modest volume gains, stable pricing, and normalized inventories. CDMO volumes rose sharply on YoY basis, supported by proprietary agro and pharma order sales.

**The Nutrition and Health Solutions** Business segment witnessed substantial YoY volume growth, primarily fueled by significant increases in Cosmetic-grade demand, with new cGMP facility receiving exceptional response. Feed volumes remained low due to cautious buying by the customers, with marginal price softening. Choline products saw sustained YoY growth, and the EU's anti-dumping duty on China is expected to strengthen Jubilant's position in Choline Chloride market. We are already in touch with multiple EU customers for choline chloride sales.

**In Chemical Intermediates segment**, our strategic push towards Ethyl Acetate, led to a YoY increase in volumes. Acetic Anhydride volumes also recovered sequentially, with marginal uptick in demand from Agrochem sector. Overall, pricing in the segment stayed relatively muted. We continued with our cost focus in this quarter to improve the margins vs. last quarter.

## **Future Outlook:**

For FY26, we anticipate continued growth and improved performance, driven by advancements in our Specialty Chemicals and Nutrition businesses, and expected recovery in Acetyls portfolio. Alongside we remain committed towards our Lean 2.0 cost efficiency initiatives. We are on track to deliver the big CDMO order in early 2026, which should further accelerate our growth trajectory in coming quarters."

# Table of Contents

06

## Company Overview



13

## Growth Roadmap



18

## Q1'FY26 Highlights



25

## Business Segments Update






# Company Overview



*Visuals of our New Diketene Derivatives Plant in Gajraula*



## JVL has a rich legacy spread over the last 45 years and 4 major chapters



## 3 business verticals: Specialty Chemicals, Nutrition & Health Solution, and Chemical Intermediates



1

### Specialty Chemicals

- CDMO
- Fine Chemicals
- Pyridine and Picolines

#### Globally #1

- Bio-Pyridine,
- Bio Beta Picoline
- 36 Pyridine Derivatives

2

### Nutrition & Health Solutions

- Animal Nutrition and Health Solutions
- Human Nutrition Solutions

#### Globally #2

in Vitamin B3

#### Domestic leader

in Vitamin B4

3

### Chemical Intermediates

- Acetic Anhydride
- Acetaldehyde
- Ethyl Acetate
- Bio Acetic Acid


#### Globally #2

in Acetic Anhydride  
Merchant Market

## Specialty Chemicals and Pharma are biggest revenue contributors while exports constitute >40% of business

### Business wise Split


Q1'FY26



Specialty Chemicals  
and Nutrition  
contribute >60% of revenues

### Application wise Split


Q1'FY26



Pharma and Nutrition  
are the biggest contributors  
with ~53% of revenue

### Geography wise Split

Q1'FY26



North America,  
& EU  
drive >30% of revenue

## World class Manufacturing facilities



### Gajraula

Uttar Pradesh, India

Integrated facility for  
Specialty Chemicals &  
Chemical Intermediates

**463 acres**



### Bharuch

Gujarat, India

CDMO & Fine Chemicals  
Nutrition and Chemical  
Intermediates

**310 acres**




### Nira

Maharashtra, India

Chemical Intermediates  
Facility

**144 acres**



### Savli

Gujarat, India

Animal Nutrition  
& Health Solutions Facility

**109 acres**



### Ambernath

Maharashtra, India

Microbial Control  
Solutions Facility

**3.5 acres**

**2300+ people**

**130+ products**

**1500+ customers**

### Operational Capabilities

Multi-Chemistry,  
Multi-Product  
Expertise

Continuous & Batch  
processes

World Class cGMP  
facility; US FDA  
inspected

Responsible Care, Tfs  
commitment;  
Ecovadis Gold

Ecologically  
Harmonized Practices

Health & Safety  
benchmarking global  
performance

## Significant investments in R&D and Innovation



R&D Center G. Noida UP, India



Pilot Plant at Gajraula UP, India

**3**  
R&D Centers

**~150**  
Scientists

**~30**  
PhDs

# Experienced and Energized Executive Leadership Team



**SS Bhartia**  
Chairman



**HS Bhartia**  
Co-Chairman & Whole  
Time Director



**Deepak Jain**  
CEO & MD  
*20 yrs exp*

## Business Leaders

### Specialty Chemicals



**Ambrish Dixit**  
President, Head of  
Specialty Chemicals  
*24 yrs exp*



**Yuvraj B**  
Business Head  
CDMO  
*18 yrs exp*



**Anurag Krishan**  
Business Head  
Fine Chemicals  
*19 yrs exp*



**Amit Saini**  
Business Head  
Pyridine & Picolines  
*21 yrs exp*

### Nutrition & Health



**Ashish Kr. Sinha**  
Business Head Animal  
& Human Nutrition  
*25 yrs exp*



**Rishi Gangwar**  
Business Head  
Nutrition & Health Ingredients  
*21 yrs exp*



**Vishal Kadam**  
Business Head  
Human Nutrition  
*27 yrs exp*

### Chemical Intermediates



**Himanshu Dhapola**  
Business Head Acetyls  
*22 yrs exp*

## Function Leaders



**Varun Gupta**  
President, Chief  
Financial Officer  
*20 yrs exp*



**Birajeev Singh**  
Head of Supply Chain  
*23 yrs exp*




**Parthasarathy  
Basu**  
Head of Strategy  
and M&A  
*17 yrs exp*



**Sanjeev Kumar**  
Head of Quality &  
Regulatory Affairs  
*26 yrs exp*



**Vijay Kumar Srivastava**  
President, Chief of Operation  
& Whole Time Director  
*24 yrs exp*



**Vinita Koul**  
Head of HR  
*27 yrs exp*



# Growth Roadmap

(Recap and Progress  
Update)

We set out on an ambitious growth path – Pinnacle 345



# PINNACLE 3.4.5

**3** times  
REVENUE



**4** times  
EBITDA



**5** year  
HORIZON



# Pinnacle Growth Pillars and Enablers



## PINNACLE 3.4.5

### G R O W T H P I L L A R S

★ New Growth Areas

#### A Specialty Chemicals

##### Pyridine & Picoline

Retain Global leadership (#1 position, cost leadership)

★ **Scale up Oilfield chemicals**

##### Fine Chemicals

**P&P derivatives:** Maintain leadership position

**Diketene derivatives:** Expand portfolio; Top 3 globally

★ **Cosmetics/Microbial: Rapid Scale-up; leverage customer/products**

##### CDMO

**Pharma & Agro:** Rapid Scale-up - Europe/US/Japan

★ **Semi-con: Rapid scale-up; new technologies through partnerships**

#### B Nutrition & Health solutions

##### Animal Nutrition

**Feed Vit B3:** Extend global leadership position

**Feed Vit B4:** Consolidate domestic leadership

**Pre-mixes:** Leadership in India and neighboring markets

##### Human Nutrition

**Cosmetic/Food grade B3:** Rapid Scale-up

**Choline Salts:** Anchor products for food segment

★ **Foray into Premix / other vitamins**

#### C Chemical Intermediates

##### Acetic Anhydride

Maintain global leadership position in merchant market

Optimize cost structure

**Other Products (Ethyl Acetate, Acetaldehyde, Bio-Acetic Acid, Propionic Anhydride)**

Continue to scale in focused markets/ customers  
Optimize cost structure

#### D

#### ENABLERS

Customer-first approach  
(Key Account Mgmt)

World-class Ops  
Best-in-class on Safety,  
Quality, ESG

Deep R&D & Tech focus

Digital transformation

Agile Supply Chain

People / Org

# Our Pinnacle journey in last one year: Good momentum across our key businesses...



Business	Key Achievements
Pyridine & Picoline	<ul style="list-style-type: none"> <li>Maintained global leadership and market share in Pyridine and Beta-Picoline</li> <li>Increased SOW in AP/APQ across customers</li> </ul>
Fine Chemicals	<ul style="list-style-type: none"> <li>15%+ revenue growth in FY25; Maintained leadership across 36 Pyridine Derivatives</li> <li>Good traction in Diketene Derivative with high utilization levels; capacity debottlenecking/expansion already initiated for new products</li> <li>Expanded Cosmetic portfolio with good initial traction with key MNC customers</li> </ul>
CDMO	<ul style="list-style-type: none"> <li>Pharma: 2x funnel expansion; good traction with innovators and tier-1 CDMOs across EU/US/Japan</li> <li>Agro: 2 scale contracts with innovators; multiple other discussions in different stages</li> <li>Semicon: 12+ opportunities in funnel; investments in R&amp;D and dedicated team</li> </ul>
Nutrition	<ul style="list-style-type: none"> <li>B3: Maintained leadership in feed; ramp-up in cosmetic and food grade with new plant commissioning</li> <li>Animal Nutrition: 15% revenue growth in FY25; High traction in exports markets including Europe; specialty portfolio growth at 16%</li> <li>Human Nutrition: Dedicated team, ramp-up in CC/CBT with marquee customers and in process of launching premixes; 2-3 more human grade products in pipeline</li> </ul>
Acetyls	<ul style="list-style-type: none"> <li>Retained market share in both Domestic and Europe market for Acetic Anhydride</li> <li>Increase in volumes across other key products: Ethyl Acetate and Acetaldehyde</li> <li>Continuous focus on cost optimization and capacity Debottlenecking</li> </ul>

Note: 1) Starting FY25 Base


# ...enabled through significant progress across our key capability pillars (not exhaustive)



Pillars	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26
<b>Customer</b>	Roadshows across EU/ US/ Japan; 120+ customer meetings; introduction to new strategy and priorities	Secured CDMO order from Agro Innovator #1 Forayed into Semiconductor chemicals	Secured CDMO order from Agro Innovator #2 (\$300M)	Funnel expansion across Pharma/Agro/Semicon CDMO/FC/Nutrition opportunities; 70+ high priority funnel	In-process of launching of Human Nutrition pre-mixes Ramp-up of Cosmetic Grade Nia (new customers)
<b>R&amp;D Focus</b>	Streamlining of R&D pipeline to align with Pinnacle priorities; 40+ focused projects	Development of 8-10 new products	Leadership Hiring: Senior VP- R&D joined	Established dedicated team to optimize VC for existing and pipeline products	Expanded the team to 150+ scientists; build out of Human Nutrition R&D
<b>Operations</b>	Bharuch GMP: USFDA audit with zero 483 Lean acceleration: 120+Cr\$ of savings	Roll out of productivity, energy and efficiency initiatives across sites	Launched dedicated Technology Cell Commissioned- Cosmetic Grade Niacinamide Facility	Received WEF Lighthouse award	First batch delivered for Agro Innovator #1 CDMO Lean 2.0 launched with 100cr+ savings target Integrated GenAI across R&D and other functions
<b>ESG/ Safety</b>	Launch of 5S Program Expansion of Project Apollo	Increased thrust on Safety Program	Launch of new program in Process Safety Mgmt	Eco Vadis and DJSI ratings British Safety Awards O2 contract in Bharuch	Launch of new program in Transporters Safety Mgmt
<b>People/ Org</b>	Streamlining of top org structure to bring more agility and focus on Pinnacle priorities	New CFO and SCM Head joined	Technology Cell Head Joined	BD teams expansion in Japan and Europe Human Nutrition Head joined Great place to work certified	New Projects Head joined



# Q1'FY26 Highlights





## Market Overview Q1'FY26 : Volumes gradually recovering across segments, though short-term tariff related uncertainty remains



### P H A R M A

- Volumes remained steady across segments, especially in our core products in Fine Chemicals
- The paracetamol segment remained muted given the low demand and utilization levels.
- Prices remain stable (vs Q4'FY25) across various segments; Customers awaiting clarity on tariff situation

### A G R O C H E M

- Agrochemical volumes grew both globally and in India; Pyridine-based Agrochemical products experienced a steady recovery in volumes
- Prices in Pyridine & Picolines products experienced short-term volatility after seeing stability through FY25

### N U T R I T I O N

- Choline (B4) demand remained steady; Positive tailwinds due to EU tariffs in coming quarters for non-Chinese players
- Niacinamide end-demand remained steady although customers delayed offtake, preferring to reduce inventory levels

# Key business highlights Q1'FY26

Core product platforms continue to drive performance; Acetyls portfolio saw some recovery with increasing momentum across AA and EA products

- **Pyridine & Picoline:** Globally #1 position in P&P (only scaled non-Chinese player), QoQ volume growth driving overall sales growth despite some price volatility
- **Niacinamide:** Maintained leadership position in feed grade with improving realizations driven by increasing cosmetic grade sales on YoY and QoQ basis; Nia cosmetic grade plant stabilizing
- **Choline:** Maintained #1 position in Dry CC domestic market; Volumes grew QoQ and YoY
- **Acetyls:** Retained market share in Acetic Anhydride with QoQ volume growth; EA volumes grew YoY

Steady share of Specialty & Nutrition; Improved customer traction driving robust pipeline

- 63% revenue share & 90% EBITDA share of Specialty & Nutrition in portfolio
- **KAM program showing traction with higher inbound queries across** CDMO Pharma, Agro and Semicon; 70+ high priority opportunities in funnel

Increasing revenue share from US & ROW; short-term volume drop in EU

- **US Revenue grew 11% YoY while ROW revenue grew 45% YoY driven by Spec Chem and Nutrition**
- **EU volumes saw short-term impact** driven by reduced offtake across Spec Chem & Nutrition
- **Continued push on Key Accounts yielding traction** in terms of bigger pipeline; BD team expansion across US, EU & Japan

Unlocking efficiency; continuous focus on Safety, ESG and 5S

- **Lean 2.0 cost reduction initiatives underway:** target of realizing 100cr+ savings
- **Initiated GenAI usage at R&D** to bring agility in pipeline and product development
- **Safety, ESG and 5S programs on track**

Continuous investments for future growth

- **Capex completed** and first batch delivered for one Agro CDMO order
- **Capex on-track** for the \$300M Agro order; **Bharuch new boiler** slated to be commissioned in Q2
- **Debottlenecking activities ongoing to unlock** capacities for core platforms (diketene, pyridine)
- Detailed engineering initiated for the **new MPP plant in Gajraula**

# Financial Results Overview | Q1'FY26 Consolidated

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Total Revenue	1,024	1,051	1,038	-1%	1%
Total EBITDA	119	155	153	-1%	29%
EBITDA Margin (%)	12%	15%	15%		
Profit After Tax	49	74	75	1%	54%
Profit After Tax Margin (%)	5%	7%	7%		
Basic and Diluted EPS (Rs.)	3.1	4.7	4.7	1%	54%

## Revenue & EBITDA during the quarter was impacted on account of :



### Specialty Chemicals

QoQ volume growth in Pyridine and its derivatives

Diketene derivatives - continued traction


YoY funnel growth in CDMO portfolio across Agro, Pharma and Semi-con



### Nutrition & Health Solutions

Choline volumes – YoY & QoQ volume growth seen

Niacinamide realizations improved YoY & QoQ with higher cosmetic grade sales; Feed prices seeing some volatility



### Chemical Intermediates

Acetic Anhydride volumes grew driven by recovering agro-demand but prices remained muted

EA prices continue to be at lower end of spectrum however volume push continued




### Lower Input costs

Lower RM costs coupled with impact of Lean initiatives helped in increasing competitiveness and expanding margins

1. All figures are in Rs Crore unless otherwise stated

# Highest Q1 EBITDA margin of 14.8% over last four years

## JVL EBITDA




## Key Drivers

- **Increasing revenue share of Specialty Chem + Nutrition BUs**
- **Increasing share of high-value products within each BU portfolio** e.g., increasing share of cosmetic/food grade B3, higher growth from new Diketene products, etc.
- **Cost measures:** Lean 2.0 initiatives across energy, operational efficiency, supply chain and overheads

# Portfolio Shift: Spec Chem and Nutrition continue to drive EBITDA; Chemical Intermediates share inching with marginal recovery



Segment-wise EBITDA Share (%)




# EBITDA trends: Secular YoY EBITDA growth in Spec Chem; stable margins in Nutrition despite short-term order pushouts; marginal recovery in Acetyls

## Specialty Chemicals

### EBITDA (Rs Cr.)

Y.o.Y Growth 52%  
Q.o.Q Growth 1%




- **Notable increase in the volumes** of Pyridine derivatives, Diketene derivatives on QoQ basis
- **CDMO sales increased** on both QoQ and YoY basis driven by better mix and higher YoY volumes

## Nutrition

### EBITDA (Rs Cr.)

Y.o.Y Growth 8%  
Q.o.Q Growth -16%




- **YoY growth in Nutrition sales and volumes** led by Choline
- QoQ performance led by **Niacinamide pricing pressures** and lower volumes led by order-pushouts

## Chemical Intermediates

### EBITDA (Rs Cr.)

Y.o.Y Growth -53%  
Q.o.Q Growth 63%




- **QoQ growth** driven by shift in product mix and cost savings initiatives
- **YoY variance** due to **price erosion** from LY; Overall Acetyls volumes grew YoY

% EBITDA Margins – Before adjustment of Unallocated corporate expense/Income





## Business Segments Overview



# 1 Specialty Chemicals | Market, Business & Financial Highlights

## MARKET HIGHLIGHTS



Pharma

- Continued improvement in demand observed
- YoY demand growth remained strong
- Steady pricing trend maintained



Agrochemical

- Volumes showed modest, gradual growth
- Stable pricing trend observed
- Inventory levels stabilizing post-destocking



CDMO

- Increased traction from customers across Pharma, Agro and semi-conductor segments, driven by supply chain diversification imperatives
- Traction with cosmetics and nutrition customers as well

## FINANCIAL HIGHLIGHTS

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	431	487	478	-2%	11%
% Share of Overall Revenue	42%	46%	46%		
EBITDA	86	129	130	1%	52%
% EBITDA Margin	20%	27%	27%		
% Contribution to EBITDA <sup>2</sup>	59%	76%	76%		

## BUSINESS DRIVERS

- Segment revenue growth was led by higher Fine Chemicals and CDMO sales
- Margins continued to remain elevated on account of :
  - Higher sales from high margin orders within Specialty portfolio
  - Steady pricing in select Pyridine and Diketene Derivatives
  - Continuous cost optimizations measures undertaken

1. All figures are in Rs Crore unless otherwise stated.

2 Before adjustment of Unallocated corporate expense/income



# Nutrition & Health Solutions | Market, Business & Financial Highlights

## MARKET HIGHLIGHTS



- Volumes were low as buyers delayed shipments, opting to maintain lower inventory levels
- Overall Pricing witnessed modest softening



- Cosmetic-grade demand surged on both QoQ and YoY basis
- New cGMP facility receiving exceptional response
- Steady sequential growth in food grade volumes



- Sustained strong YoY volume traction
- EU's anti-dumping duty on China, to boost Jubilant's competitive edge in Choline Chloride

## FINANCIAL HIGHLIGHTS

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	186	190	179	-6%	-4%
% Share of Overall Revenue	18%	18%	17%		
EBITDA	23	29	25	-16%	8%
% EBITDA Margin	12%	16%	14%		
% Contribution to EBITDA <sup>2</sup>	16%	17%	14%		

## BUSINESS DRIVERS

- Revenue saw a modest decline, impacted by lower Niacinamide prices and shipment delays as customers opted for lean inventories
- YoY increase in Choline Chloride volumes and animal nutrition specialty business
- The sequential drop in EBITDA was mainly driven by lower volumes and prices of Niacinamide

1. All figures are in Rs Crore unless otherwise stated.  
2 Before adjustment of Unallocated corporate expense/income

# Chemical Intermediates | Market, Business & Financial

## 3 Highlights

### MARKET HIGHLIGHTS



- Acetic Anhydride volumes saw an uptick during the quarter driven by recovery in agrochem segments
- Ethyl Acetate volumes remained a key area of strategic emphasis



- Acetic Acid prices declined marginally during the quarter
- Through ongoing cost optimization measures and easing freight rates, margin expansion expected in few quarters



- Segment prices remained steady on a sequential basis

### FINANCIAL HIGHLIGHTS

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	408	375	381	2%	-7%
% Share of Overall Revenue	40%	36%	37%		
EBITDA	36	10	17	63%	-53%
% EBITDA Margin	9%	3%	4%		
% Contribution to EBITDA <sup>2</sup>	25%	6%	10%		

### BUSINESS DRIVERS

- Revenue improved QoQ, supported by an increase in Acetic Anhydride volumes
- EBITDA improved sequentially, supported by higher Acetic Anhydride volumes and a slight reduction in input costs for Acetic Acid.

1. All figures are in Rs Crore unless otherwise stated.  
2. Before adjustment of Unallocated corporate expense/Income

# Annexures

## Annexure I - Income Statement | Consolidated – Q1'FY26

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	QoQ	YoY
<b>Revenue from operations</b>					
a) Sales/Income from operations	1010	1038	1029	-1%	2%
b) Other operating income	14	13	9	-35%	-39%
<b>Total revenue from operations</b>	<b>1024</b>	<b>1051</b>	<b>1038</b>	<b>-1%</b>	<b>1%</b>
Other income	10	8	11	34%	17%
<b>Total income</b>	<b>1034</b>	<b>1060</b>	<b>1049</b>	<b>-1%</b>	<b>1%</b>
<b>Expenses</b>					
a) Cost of materials consumed	532	481	449	-7%	-16%
b) Purchases of stock-in-trade	7	32	32	1%	338%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	-11	20	38	94%	-453%
d) Employee benefits expense	102	96	108	13%	6%
e) Finance costs	14	14	13	-9%	-11%
f) Depreciation and amortisation expense	39	39	41	4%	5%
g) Other expenses:					
- Power and fuel expense	118	104	100	-4%	-15%
- Others	166	171	168	-2%	1%
<b>Total expenses</b>	<b>968</b>	<b>958</b>	<b>949</b>	<b>-1%</b>	<b>-2%</b>
Profit before share of loss of an associate (3-4)	66	102	100	-2%	51%
Share of loss of an associate	0		0		
<b>Profit before tax</b>	<b>66</b>	<b>102</b>	<b>100</b>	<b>-2%</b>	<b>51%</b>
<b>Tax expense</b>					
- Current tax	12	25	23	-8%	86%
- Deferred tax charge	5	2	2		
<b>Net profit for the period/year</b>	<b>49</b>	<b>74</b>	<b>75</b>	<b>1%</b>	<b>54%</b>
Earnings per share of ₹ 1 each					
Basic (₹)	3.1	4.7	4.7		
Diluted (₹)	3.1	4.6	4.7		

1. All figures are in Rs Crore unless otherwise stated.

Expenses covered in Other expenses include i) Consumption of stores and spares and packing materials. ii) Repairs and maintenance, iii) Freight & forwarding (including ocean freight). iv) Others

## Annexure II: Income Statement Segmental – Q1'FY26

Particulars <sup>1</sup>	Q1'FY25	Q4'FY25	Q1'FY26	QoQ (%)	YoY (%)
<b>Revenue</b>					
Speciality Chemicals	431	487	478	(2%)	11%
Nutrition & Health Solutions	186	190	179	(6%)	(4%)
Chemical Intermediates	408	375	381	2%	(7%)
<b>Total Revenue from Operations</b>	<b>1,024</b>	<b>1,051</b>	<b>1,038</b>	<b>(1%)</b>	<b>1%</b>
<b>Reported EBITDA</b>	<b>119</b>	<b>155</b>	<b>153</b>	<b>(1%)</b>	<b>29%</b>
Speciality Chemicals	86	129	130	1%	52%
Nutrition & Health Solutions	23	29	25	(16%)	8%
Chemical Intermediates	36	10	17	63%	(53%)
Unallocated Corporate & One-Off (Expenses)/Income	-25	-14	-19	-	-
<b>PAT</b>	<b>49</b>	<b>74</b>	<b>75</b>	<b>1%</b>	<b>54%</b>
<b>EPS</b>	<b>3.1</b>	<b>4.7</b>	<b>4.7</b>	<b>1%</b>	<b>54%</b>
<b>Reported EBITDA Margins</b>	<b>12%</b>	<b>15%</b>	<b>15%</b>		
Speciality Chemicals	20%	27%	27%		
Nutrition & Health Solutions	12%	16%	14%		
Chemical Intermediates	9%	3%	4%		
<b>Net Margin</b>	<b>5%</b>	<b>7%</b>	<b>7%</b>		

1. All figures are in Rs Crore unless otherwise stated.

## Annexure III: Debt Position| As on 30<sup>th</sup> June 2025


Particulars <sup>1</sup>	30-Jun-24	31-Mar-25	30-Jun-25
Long Term Borrowings	450	453	448
Short Term Borrowings	291	303	360
<b>Total Gross Debt</b>	<b>741</b>	<b>756</b>	<b>808</b>
Cash & Equivalent	64	98	107
<b>Total Net Debt</b>	<b>677</b>	<b>658</b>	<b>700</b>
YoY change			3%

- The capex for the quarter was Rs 54 Crore, which was primarily utilized towards the upcoming CDMO Plant at Bharuch.

## Annexure III - Conference Call Details

**Date : July 31<sup>st</sup>, 2025**

**Time : 05:00 pm IST**

Diamond Pass Log-In	
Pre-registration:	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p> <p> <a href="#">Click here to ExpressJoin the Call</a></p> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode &amp; pin to connect to call.</p>
Conference Dial-In Numbers	
Universal Access:	<p><b>+ 91 22 6280 1141</b></p> <p><b>+ 91 22 7115 8042</b></p>
Toll Free Number:	<p>USA: <b>1 866 746 2133</b></p> <p>UK: <b>0 808 101 1573</b></p> <p>Singapore: <b>800 101 2045</b></p> <p>Hong Kong: <b>800 964 448</b></p>
Audio Link:	<p>The Audio link will be available on the company website. Please access the link here -</p> <p><a href="https://jubilantingrevia.com/investors/financials/quarterly-results">https://jubilantingrevia.com/investors/financials/quarterly-results</a></p>



## For More Information



Thank you for your time

Jubilant Ingrevia Limited is a globally integrated Life Sciences & Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad portfolio of over 130+ products and customized solutions that are innovative, cost-effective and conform to global quality standards.

It has over 40 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharma, agrochemicals and semi-conductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50 plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ over 145 scientists working on cutting-edge research and innovation.

Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies.

For more information, please visit: [www.jubilantingrevia.com](http://www.jubilantingrevia.com)

## For Investors:

**Pavleen Taneja**

Jubilant Ingrevia Limited.

☎ Ph: +91 120 436 1000

✉ E-mail: [pavleen.taneja@jubl.com](mailto:pavleen.taneja@jubl.com)

**Siddharth Rangnekar, CDR India**

☎ Ph: +91 22 6645 1209

✉ E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

☎ **For Media:**

✉ **Sandipan Ghatak**

Ph: +91 120 436 1062

E-mail: [sandipan.ghatak@jubl.com](mailto:sandipan.ghatak@jubl.com)